Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903708 · ClinicalTrials.gov registry record · Phase 1
LY2275796 in Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00903708: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00903708 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00903708, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Primary Objective: * To determine a recommended Phase 2 dose of LY2275796 that may be safely administered to patients with advanced cancer, with prospects for therapeutic biologic effects. This will require simultaneous: * monitoring of toxicities \& determination of maximal tolerated dose (MTD) * detecting eIF-4E target inhibition in tumor * pharmacokinetic measurements Secondary Objectives: * To estimate pharmacokinetic parameters of LY2275796 and explore pharmacokinetic/pharmacodynamic relationships * To document any antitumor activity observed with LY2275796
Interventions
- DRUG LY2275796
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903708
The ClinicalTrials.gov registry entry for NCT00903708 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2275796 is the first listed.
NCT00903708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00903708 about?
NCT00903708 is a clinical study titled "LY2275796 in Advanced Cancer". Primary Objective: * To determine a recommended Phase 2 dose of LY2275796 that may be safely administered to patients with advanced cancer, with prospects for therapeutic biologic effects. This will require simultaneous: * monitoring of toxicities \& determination of maximal tolerated dose (MTD) * ...
What is the current status of trial NCT00903708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00903708?
The interventions under investigation include: LY2275796 (DRUG).
Who is sponsoring clinical trial NCT00903708?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.